Effect of Ivabradine on Heart Failure: A 2024 Meta-Analysis
Akshay Maharaj1, Matthew B Maturasingh2, Alvin Khangembam3
1Internal Medicine, Port of Spain General Hospital, Chaguanas, TTO.
Cureus
|February 13, 2025
Summary
Ivabradine significantly reduces heart rate and improves left ventricular ejection fraction in heart failure patients. However, this meta-analysis found no significant impact on cardiovascular mortality or hospital readmissions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ivabradine is a heart rate-lowering agent.
- Its efficacy in heart failure is primarily attributed to HR and LVEF effects.
- Broader clinical impact remains under investigation.
Purpose of the Study:
- To conduct a meta-analysis on ivabradine's effectiveness in chronic heart failure.
- To evaluate its impact on clinical outcomes and cardiovascular parameters beyond HR and LVEF.
Main Methods:
- Systematic search of five databases (PubMed, Medline, Clinical Trials, Embase, Cochrane).
- Inclusion of 11 randomized controlled trials (1,687 participants).
- Analysis of cardiovascular mortality, hospital readmissions, exercise capacity, HR, LVEF, MLWHF, NT-proBNP, BNP, and left ventricular volume.
Main Results:
- Significant reduction in heart rate (MD, -11.7) and improvement in LVEF (MD, 3.03) with ivabradine.
- Significant reduction in NT-proBNP levels (MD, -384).
- No significant reduction in cardiovascular mortality (RR, 0.79) or hospital readmissions (RR, 0.53).
Conclusions:
- Ivabradine effectively reduces heart rate and improves LVEF in heart failure patients.
- No significant benefits were observed for cardiovascular mortality, hospital readmissions, or other assessed clinical outcomes.
Keywords:
article reviewheart failure with preserved ejection fractionheart failure with reduced ejection fractionivabradineleft ventricular ejection fraction (lvef)pharmacotherapy for heart failureMore Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.4K
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.4K
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
374
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374
01:26Heart Failure Drugs: Inotropic Agents
504
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
504
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
762
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
762